Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
B

Ratings ESG MSCI

Ratings Ipca Laboratories Limited: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Ipca Laboratories Limited
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Ipca Laboratories Limited
  • The firm trades with high earnings multiples: 31.56 times its 2027 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Rating Financials

Ipca Laboratories Limited SectorIndia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Ipca Laboratories Limited SectorIndia

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Ipca Laboratories Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Ipca Laboratories Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Ipca Laboratories Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
4.63B
B
1,057B
A
625B -
BBB
- -
435B
AA
-
363B
AA
296B
AAA
249B
A
222B
A
209B
A
165B
AA
Average 362.54B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. IPCALAB Stock
  4. 524494 Stock
  5. Ratings Ipca Laboratories Limited